ADAPTIMMUNE THERAPEUTICS PLC (NASDAQ:ADAP) Files An 8-K Other Events
Item 8.01 Other Events.
On May25, 2017, Adaptimmune Therapeutics plc (the Company) issued
a press release announcing that it has initiated its study of
NY-ESO SPEAR T-cells targeting NY-ESO in combination with
KEYTRUDA (pembrolizumab), an anti-PD-1 inhibitor marketed by
Merck Co.,Inc., Kenilworth, NJ, USA (known as MSD outside the US
and Canada), in patients with multiple myeloma. The text of the
press release is attached as Exhibit99.1 and is incorporated by
reference herein.
The information contained in Item 8.01 of this Form8-K, including
the attached Exhibit99.1, shall not be deemed filed for purposes
of Section18 of the Securities Exchange Act of 1934, as amended
(the Exchange Act), or incorporated by reference in any filing
made by the Company under the Securities Act of 1933, as amended,
or the Exchange Act, except as expressly set forth by the Company
by specific reference in such a filing.
Item 9.01 Financial Statements and
Exhibits.
(d) Exhibits. The following exhibit is furnished as part of this
Report on Form8-K:
|
ExhibitNo. |
|
DescriptionofExhibit |
|
99.1 |
Press Release dated May25, 2017 |
About ADAPTIMMUNE THERAPEUTICS PLC (NASDAQ:ADAP)
Adaptimmune Therapeutics plc is a clinical-stage biopharmaceutical company. The Company is focused on cancer immunotherapy products based on its T-cell receptor (TCR) platform. The Company has developed a platform that enables it to identify cancer targets in the form of peptides, which are short sequences of amino acids, find and genetically engineer TCRs, and produce TCR therapeutic candidates for administration to patients. The Company engineers TCRs to increase their affinity to cancer-specific peptides, including its lead target peptides, NY-ESO-1 and MAGE-A10, in order to target and then destroy cancer cells in patients. The Company’s TCR therapeutic candidates are able to target intracellular, as well as extracellular cancer antigens. The TCRs consist of approximately two associated protein chains: the alpha and beta chains. Each of the chains has approximately two regions: a variable region and a constant region. ADAPTIMMUNE THERAPEUTICS PLC (NASDAQ:ADAP) Recent Trading Information
ADAPTIMMUNE THERAPEUTICS PLC (NASDAQ:ADAP) closed its last trading session down -0.02 at 5.30 with 164,346 shares trading hands.
